Brief: Glenmark Pharma To Directly Commercialize And Distribute Ryaltris In U.S. Effective
01/04/2026 13:33
April 1 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS: GLENMARK PHARMA - TO DIRECTLY COMMERCIALIZE AND DISTRIBUTE RYALTRIS IN U.S. EFFECTIVE APRIL 1, 2026 Source text: ID:nBSE33lGVw Further company coverage: GLEN.NS ((reuters.briefs@thomsonreuters.com;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter